Accelerate Diagnostics : Material Event (Form 8-K)

Other Events.

On September 29, 2021 and September 30, 2021, Accelerate Diagnostics, Inc. (the "Company") closed certain of its previously announced privately negotiated exchanges (the "Exchange Transactions") with certain holders of its 2.50% Convertible Senior Notes due 2023 (the "Notes"). In connection with the closing of these Exchange Transactions, certain holders exchanged approximately $46 million in aggregate principal amount of Notes, and the Company issued an aggregate of 5,945,718 shares of its common stock to such holders.

For additional information regarding the Exchange Transactions and the related exchange agreements, see the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on September 23, 2021.

Additionally, on September 30, 2021, the Company closed the remaining third tranche of its previously announced private placement offering (the "Private Placement") of shares of the Company's common stock. In connection with the closing of the third tranche of the Private Placement, the Company issued an aggregate of 67,276 shares of its common stock for proceeds of approximately $0.5 million.

For additional information regarding the Private Placement and the related securities purchase agreement, see the Current Reports on Form 8-K filed with the SEC on December 28, 2020, February 23, 2021, April 14, 2021 and September 23, 2021.